Metopirone (metyrapone) NDC 76336-455

NDC codes

FDA NDC Directory

Product NDC (as listed)76336-455Labeler and product segments. Claims need a package NDC.

Product NDC at billing width76336-0455Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
76336-455-18	76336045518	18 CAPSULE, GELATIN COATED in 1 BOTTLE (76336-455-18)Marketed from Jan 25, 1962

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Metopirone
Generic name (nonproprietary): metyrapone
Active ingredients: Metyrapone — 250 mg/1
Dosage form: Capsule, Gelatin coated
Route: Oral
Labeler: HRA Pharma Rare Diseases
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 012911
Marketing start: Jan 25, 1962
Listing expires: Dec 31, 2027
Other FDA classes: Adrenal Steroid Synthesis Inhibitors (Mechanism)
Identifiers: Product ID 76336-455_47d0c075-05db-df45-e063-6294a90a4e12SPL ID 47d0c075-05db-df45-e063-6294a90a4e12SPL set ID 3a27d0ef-83a7-4e1c-9430-46a3326ee8d8RxCUI 105450, 199772UNII ZS9KD92H6V
Pharmacologic class: Adrenal Steroid Synthesis Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N476336045518 followed by a unit qualifier and the quantity

Package 76336-0455-18. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 7, 2026.

Indications (excerpt from the label)

Metopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients. Metopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)